Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Correction for O’Donnell et al., Stroke 39 (5) 1638-1646.
Stroke. 2008;39:e147
doi: 10.1161/STROKEAHA.107.000006
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions

(Stroke. 2008;39:e147.)
© 2008 American Heart Association, Inc.

Correction

In the article entitled "Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review" by O’Donnell et al,1 the authors report two errors. First, in Table 3, under Cilostazol’s Serious Vascular Event Risk Reduction (95% CI) column, the values should be "(0.41–0.91)" instead of "(0.41–0.01)." Second, on page 1641, the reference number of the "Efficacy" category under the "Cilostazol Versus Control" Section should be "41" instead of "42."

The authors regret these errors.

The corrected version can be viewed online at http://stroke.ahajournals.org.

1[Correction for Vol 39, Number 5, May 2008. Pages 1638–1646.]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions